scholarly journals Alternative treatment options for periocular basal cell carcinoma: a narrative review

2021 ◽  
Vol 0 ◽  
pp. 0-0
Author(s):  
Kristina Erikson ◽  
Anton Brosig ◽  
Michael Walter Zimbelmann ◽  
Steffen Emmert ◽  
Yongwei Guo ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Alternative Treatment ◽  
Treatment Options ◽  
Narrative Review

A review of emerging and non-US FDA-approved topical agents for the treatment of basal cell carcinoma

2021 ◽  
Author(s):  
Natalie Kash ◽  
Sirunya Silapunt
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Gold Standard ◽  
Treatment Options ◽  
Tumor Characteristics ◽  
Tumor Clearance ◽  
Superficial Basal Cell Carcinoma ◽  
Us Fda ◽  
Cure Rates

Although surgical therapy continues to be the gold standard for the treatment of basal cell carcinoma given high cure rates and the ability to histologically confirm tumor clearance, there are a number of nonsurgical treatment options that may be considered based on individual tumor characteristics, functional and cosmetic considerations, patient comorbidities and patient preference. Topical 5-fluorouracil 5% cream and imiquimod 5% cream have been US FDA-approved for the treatment of superficial basal cell carcinoma. Additionally, a number of new and emerging topical agents and techniques have been described for the treatment of basal cell carcinoma and will be reviewed herein.

Basal Cell Carcinoma: Epidemiology, Risk Factors, and Treatment Options

2017 ◽  
Author(s):  
Jeffrey M Farma ◽  
Elena P Lamb
Keyword(s):  
Risk Factors ◽  
Photodynamic Therapy ◽  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Treatment Options ◽  
Sun Exposure ◽  
Hedgehog Pathway ◽  
Treatment Modalities ◽  
Genetic Syndromes

Ultraviolent (UV) solar radiation is considered to be the dominant risk factor for development of basal cell carcinoma (BCC). The development of BCC is thought to arise from intense, intermittent sun exposure leading to burns. Identifying patients with high-risk factors for developing BCC includes chronic immunosuppression, exposure to ionizing radiation, and certain genetic syndromes. Primary treatment goals of BCC include cure of tumor with maximal preservation of function. Although rarely metastatic, BCC can produce substantial local destruction. Treatment modalities can be divided into surgical and nonsurgical therapies, although surgical therapy is the mainstay of treatment. Superficial therapies, such as topical imiquimod or 5-fluorouracil, photodynamic therapy, or cryotherapy, may be effective for anatomically challenging locations where surgery or radiation is contraindicated, but the cure rates of these approaches are lower compared with surgery. Recent FDA-approved hedgehog pathway inhibitors include vismodegib and sonidegib for patients who have exhausted surgical and radiation options for treating advanced BCC. This review contains 4 figures, 5 tables, and 25 references. Key words: cryosurgery, cutaneous basal cell carcinoma, hedgehog pathway inhibitors, Mohs micrographic surgery, pathologic risk factors, photodynamic therapy, radiation therapy, surgical margins, topical therapies 

scholarly journals Vismodegib: The Proof of Concept in Basal Cell Carcinoma

2014 ◽  
Vol 8 ◽  
pp. CMO.S14569 ◽  
Author(s):  
Narjiss Berrada ◽  
Siham Lkhoyali ◽  
Hind Mrabti ◽  
Hassan Errihani
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Signaling Pathway ◽  
Basal Cell ◽  
Hedgehog Signaling ◽  
Treatment Options ◽  
Locally Advanced ◽  
Scientific Data ◽  
Hedgehog Signaling Pathway ◽  
Proof Of Concept

Although basal cell carcinoma (BCC) is the most common cancer worldwide, its metastatic dissemination is exceptional. Before 2012, we had a few treatment options available for metastatic or locally advanced cases. Management of these patients was complicated due to the lack of scientific data, the deterioration of a patient's general status, the patient's advanced age, and the presence of multiple comorbidities. The hedgehog signaling pathway is dysregulated in BCC. The exploration of this signaling pathway yielded to a major milestone in the treatment of advanced BCC. Vismodegib (GDC-0449), an oral small-molecule agent that targets the Hedgehog signaling pathway, demonstrates high levels of activity in clinical trials. It was approved in January 2012 for the treatment of locally advanced or metastatic BCC. Vismodegib confirms, once again, the interest in exploring the signal transduction pathways in cancers.

Basal Cell Carcinoma: Epidemiology, Risk Factors, and Treatment Options

2017 ◽  
Author(s):  
Jeffrey M Farma ◽  
Elena P Lamb
Keyword(s):  
Risk Factors ◽  
Photodynamic Therapy ◽  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Treatment Options ◽  
Sun Exposure ◽  
Hedgehog Pathway ◽  
Treatment Modalities ◽  
Genetic Syndromes

Ultraviolent (UV) solar radiation is considered to be the dominant risk factor for development of basal cell carcinoma (BCC). The development of BCC is thought to arise from intense, intermittent sun exposure leading to burns. Identifying patients with high-risk factors for developing BCC includes chronic immunosuppression, exposure to ionizing radiation, and certain genetic syndromes. Primary treatment goals of BCC include cure of tumor with maximal preservation of function. Although rarely metastatic, BCC can produce substantial local destruction. Treatment modalities can be divided into surgical and nonsurgical therapies, although surgical therapy is the mainstay of treatment. Superficial therapies, such as topical imiquimod or 5-fluorouracil, photodynamic therapy, or cryotherapy, may be effective for anatomically challenging locations where surgery or radiation is contraindicated, but the cure rates of these approaches are lower compared with surgery. Recent FDA-approved hedgehog pathway inhibitors include vismodegib and sonidegib for patients who have exhausted surgical and radiation options for treating advanced BCC. This review contains 4 figures, 5 tables, and 25 references. Key words: cryosurgery, cutaneous basal cell carcinoma, hedgehog pathway inhibitors, Mohs micrographic surgery, pathologic risk factors, photodynamic therapy, radiation therapy, surgical margins, topical therapies 

scholarly journals Advanced treatment in basal cell carcinoma of skin

2019 ◽  
Vol 5 (1) ◽  
pp. 217
Author(s):  
Pankaj Kumar Gupta ◽  
Xuefeng Wan ◽  
Hari Krishna Kanduri ◽  
Kurelli Sai Charan Goud ◽  
Paride Abliz ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Treatment Options ◽  
Advanced Treatment ◽  
Mohs Micrographic Surgery ◽  
Micrographic Surgery ◽  
Tumor Margins ◽  
The Past ◽  
Treatment Procedures

<p class="abstract">In the past ten years, the occurrence of basal cell carcinoma (BCC) has amplified manifold. There are many treatment procedures to cure BCC, which includes micrographic surgery by means of surgical margins of 3-5mm based on size of tumor, intrusion and location. The normally used method for treatment of basal cell carcinoma is excision by surgery. The most commonly used advanced method of excision in the treatment of bcc is Mohs’ micrographic surgery (MMS). There is no proper guideline, which mentions surgery as the treatment of choice as there are no controlled randomized studies matching surgery with nonsurgical treatment options in BCC. Excision is a competent and meticulous technique as there is a low recurrence of tumor following the histological examination of tumor margins.</p><p class="abstract"> </p>

Sign in / Sign up

Export Citation Format

Share Document